Large pharma companies at TPD Summit 2026
Oct 26–29, 2026 Boston, MA ~300 attendees Website
18 large pharma companies are at TPD Summit 2026 — 22 presentations on the program. Most represented: Amgen (2 on the program), Genentech (2 on the program), Astellas (2 on the program). 6 of them have their own page in this guide. As of Oct 8, 2026.
Topic
Top represented
Showing 1–17 of 18 organizations
| Organization | TPD Summit 2026 Attendance |
|---|---|
Amgen Thousand Oaks, CA | |
Global biopharmaceutical company with medicines in oncology, inflammation, cardiovascular and bone disease, and induced proximity research. | Chair Wed Oct 28 8:20am Chair’s Opening Remarks Investment, partnering & strategy Talk Wed Oct 28 9:30am Beyond Degraders: Are We Asking the Wrong Questions in Induced Proximity? Induced proximity beyond degradation Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy Talk Thu Oct 29 2:15pm GlueScope: Accelerating Molecular Glue Discovery through Orthogonal Proteomics & Deep Screening Screening, assays & proteomics |
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets medicines. | Talk Tue Oct 27 12:30pm Talk Thu Oct 29 9:30am Optimizing the Next Generation Degraders with Better Informatics, Descriptors & Predictive Modeling AI & computational design Panel Thu Oct 29 10:00am |
Astellas Tokyo, Japan | ◇Industry Partner |
Japanese pharmaceutical company with a targeted protein degradation program, including the KRAS G12D degrader setidegrasib. | Talk Tue Oct 27 2:00pm Talk Wed Oct 28 3:00pm |
AstraZeneca Cambridge, UK | |
Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases. | Talk Wed Oct 28 2:30pm Linking Molecular Glue Binding Kinetics to Functional Performance Through Quantitative Modeling AI & computational design Talk Thu Oct 29 9:30am Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs) Degrader conjugates & tissue targeting |
Novartis Basel, Switzerland | |
Swiss pharmaceutical company developing and marketing medicines in oncology, immunology, cardiovascular disease and neuroscience. | Talk Tue Oct 27 5:00pm Modelling Targeted Protein Degradation from Cells to the Clinic AI & computational design Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Eli Lilly Indianapolis, IN | |
Global pharmaceutical company; its TuneLab platform offers biotechs AI models trained on Lilly research data. | Talk Tue Oct 27 4:30pm Accelerating Drug Discovery with Lilly TuneLab’s Federated Computing Platform AI & computational design Panel Thu Oct 29 10:00am |
Biogen Cambridge, MA | |
Develops and markets therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease. | Panel Tue Oct 27 3:10pm |
Bristol Myers Squibb Princeton, NJ | |
Global pharmaceutical company with medicines in oncology, immunology, cardiovascular disease and neuroscience, and a protein degrader pipeline. | |
GSK London, UK | |
Global biopharmaceutical company with vaccines and medicines in infectious disease, HIV, respiratory, immunology and oncology. | Talk Thu Oct 29 12:15pm Molecular Glue Discovery & Validation Using DNA-Encoded Libraries Screening, assays & proteomics |
Johnson & Johnson New Brunswick, NJ | |
Healthcare company whose Innovative Medicine segment develops medicines in oncology, immunology and neuroscience. | Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Merck & Co. Rahway, NJ | |
Global pharmaceutical company, known as MSD outside the US and Canada, developing medicines, vaccines and biologics. | Panel Wed Oct 28 10:00am Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding Investment, partnering & strategy |
Pfizer New York, NY | |
Pharmaceutical company developing and marketing medicines and vaccines across oncology, vaccines, internal medicine and other areas. | Talk Thu Oct 29 8:30am Degrader-Antibody Conjugates: Proof of Concept Through Design of a Potent BRD4 Degrading Linker-Payload Degrader conjugates & tissue targeting |
Takeda Tokyo, Japan | |
Global pharmaceutical company developing medicines in gastroenterology, rare diseases, neuroscience, oncology and plasma-derived therapies. | |
Chugai Pharmaceutical Tokyo, Japan | |
Japanese pharmaceutical company and Roche Group member developing antibody, small-molecule and mid-size peptide medicines. | Attending On the meeting’s published attendee list |
Merck KGaA Darmstadt, Germany | |
German science and technology group whose healthcare business develops medicines in oncology, neurology and immunology. | Attending On the meeting’s published attendee list |
Ono Pharmaceutical Osaka, Japan | |
Japanese pharmaceutical company developing medicines in oncology, immunology and neurology. | Attending On the meeting’s published attendee list |
Sanofi Paris, France | |
Global pharmaceutical company with medicines and vaccines in immunology, rare diseases, neurology and oncology. | Attending On the meeting’s published attendee list |
Instantly find 20 buyers from large pharma companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TPD Summit 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by the TPD & Induced Proximity Summit or its organizers. Submit a correction